首页> 美国卫生研究院文献>other >Noninvasive Digital Detection of Fetal DNA in Plasma of 4-Week-Pregnant Women following In Vitro Fertilization and Embryo Transfer
【2h】

Noninvasive Digital Detection of Fetal DNA in Plasma of 4-Week-Pregnant Women following In Vitro Fertilization and Embryo Transfer

机译:体外受精和胚胎移植后4周孕妇血浆中胎儿DNA的无创数字检测

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The discovery of cell-free fetal DNA (cfDNA) circulating in the maternal blood has provided new opportunities for noninvasive prenatal diagnosis (NIPD). However, the extremely low levels of cfDNA within a high background of the maternal DNA in maternal circulation necessitate highly sensitive molecular techniques for its reliable use in NIPD. In this proof of principle study, we evaluated the earliest possible detection of cfDNA in the maternal plasma by a bead-based emulsion PCR technology known as BEAMing (beads, emulsion, amplification, magnetics). Blood samples were collected from in vitro fertilization (IVF) patients at 2 to 6 weeks following embryo transfer (i.e., 4 to 8 week pregnancies) and plasma DNA was extracted. The genomic regions of both X and Y chromosome-specific sequences (AMELX and AMELY) were concurrently amplified in two sequential PCRs; first by conventional PCR then by BEAMing. The positive beads either for AMELX or AMELY gene sequences were counted by a flow cytometer. Our results showed that the pregnancies yielding boys had significantly higher plasma AMELY gene fractions (0.512 ± 0.221) than the ones yielding girls (0.028 ± 0.003) or non-pregnant women (0.020 ± 0.005, P= 0.0059). Here, we clearly demonstrated that the BEAMing technique is capable of reliably detecting cfDNA in the blood circulation of 4-week-pregnant women, which is only two weeks after the embryo transfer. BEAMing technique can also be used to early detect fetal DNA alterations in other pregnancy-associated disorders.
机译:母血中循环的无细胞胎儿DNA(cfDNA)的发现为无创产前诊断(NIPD)提供了新的机会。然而,在母体循环中,在母体DNA高背景中的cfDNA含量极低,因此需要高度灵敏的分子技术来可靠地用于NIPD。在这项原理研究的证明中,我们评估了通过基于珠的乳液PCR技术(称为BEAMing)(珠,乳液,扩增,磁性)在母体血浆中最早检测cfDNA的可能性。在胚胎移植后2至6周(即怀孕4至8周)从体外受精(IVF)患者收集血液样本,并提取血浆DNA。 X和Y染色体特异性序列(AMELX和AMELY)的基因组区域在两个连续PCR中同时扩增。首先通过常规PCR,然后通过BEAMing。通过流式细胞仪计数AMELX或AMELY基因序列的阳性珠。我们的结果表明,怀孕男孩的血浆AMELY基因分数(0.512±0.221)显着高于怀孕女孩(0.028±0.003)或未怀孕妇女(0.020±0.005,P = 0.0059)。在这里,我们清楚地证明了BEAMing技术能够可靠地检测4周怀孕妇女血液循环中的cfDNA,这距离胚胎移植仅两周。 BEAMing技术还可以用于及早发现其他妊娠相关疾病中的胎儿DNA改变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号